文献速递神经肿瘤

DNA修复相关多基因特征可作为胶质母细胞瘤新的预后预测指标

Identification of a DNA Repair-Related Multigene Signature as a Novel Prognostic Predictor of Glioblastoma.
PubMed 文献 · World Neurosurg · 2018-05-26

本研究利用中国胶质瘤基因组图谱中89例原发性胶质母细胞瘤RNA-seq数据作为训练队列,以癌症基因组图谱RNA-seq和GSE16011 mRNA芯片集作为验证队列,构建DNA修复相关5基因特征。该特征可将患者分为高、低风险组,低风险组总生存期更优且从替莫唑胺治疗中获益更大(P<0.05)。

要点

  • 基于APEX1、APRT、PARP2、PMS2L2和POLR2L的5基因特征可将原发性胶质母细胞瘤分为高、低风险组。
  • 低风险组预测总生存期更优,且从替莫唑胺治疗中获益更大(P<0.05)。
  • 受试者工作特征曲线显示该多基因特征预测生存的敏感性和特异性最高(P<0.05)。

核心结论

  • 在原发性胶质母细胞瘤患者中,基于5基因面板风险评分的分类可区分不同的总生存期和对替莫唑胺的反应。
  • 该5基因特征可能成为一种预测总生存期并为患者提供精准治疗的新模型。

研究设计与样本

  • 从中国胶质瘤基因组图谱RNA-seq数据集中选取89例原发性胶质母细胞瘤作为训练队列。
  • 以癌症基因组图谱RNA-seq和GSE16011 mRNA芯片集作为验证队列。
  • 采用回归分析和线性风险评分评估构建DNA修复相关特征,用Kaplan-Meier分析评估预测价值,多因素Cox回归分析判断5基因特征能否独立预测总生存期。

主要发现

  • 使用APEX1、APRT、PARP2、PMS2L2和POLR2L的5基因特征面板,将原发性胶质母细胞瘤患者分为高风险组和低风险组。
  • 低风险评分组患者预测总生存期更优,且从替莫唑胺治疗中获益更大(P<0.05)。
  • 受试者工作特征曲线显示,该多基因特征预测生存的敏感性和特异性最高(P<0.05)。

关键数值与推荐

  • 5基因特征面板包含APEX1、APRT、PARP2、PMS2L2和POLR2L。
  • 低风险组与高风险组在总生存期和替莫唑胺治疗获益方面差异有统计学意义(P<0.05)。
  • 多基因特征预测生存的敏感性和特异性最高(P<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) is an extremely challenging malignancy to treat. Although temozolomide (TMZ) is a standard treatment regimen, many patients with GBM develop chemoresistance. The aim of this study was to identify a DNA repair-related gene signature to better stratify patients treated with TMZ. METHODS: We selected 89 cases of primary GBM (pGBM) from the Chinese Glioma Genome Atlas RNA-seq dataset as the training cohort, whereas The Cancer Genome Atlas RNA-seq and Gene Set Enrichment (GSE) 16011 mRNA array sets were used as validation cohorts. Regression analysis and linear risk score assessment were performed to build a DNA repair-related signature. We used Kaplan-Meier analysis to evaluate the predictive value of the signature for overall survival (OS) in the different groups. Multivariate Cox regression analysis was used to determine whether the 5-gene signature could independently predict OS. RESULTS: Using our 5-gene signature panel of APEX1, APRT, PARP2, PMS2L2, and POLR2L, we divided patients with pGBM into high- and low-risk groups. Patients with a low-risk score were predicted to have favorable survival and greater benefit from TMZ therapy compared with patients from the high-risk group (P < 0.05). Moreover, receiver operating characteristic curves showed that the multigene signature was the most sensitive and specific model for survival prediction (P < 0.05). CONCLUSIONS: Among patients with pGBM, classification based on a risk score determined using a 5-gene panel indicated different OS and reaction to TMZ. The findings in this study demonstrate that this unique 5-gene signature could be a novel model to predict OS and provide accurate therapy for patients with pGBM.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Jin S, Qian Z, Liang T, et al. Identification of a DNA Repair-Related Multigene Signature as a Novel Prognostic Predictor of Glioblastoma. World Neurosurg. 2018. PMID: 29807183. doi:10.1016/j.wneu.2018.05.122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。